You are here: Industry Insights > COVID-19

News List

Fusion Antibodies, Queen’s University Belfast Receives Grant for COVID-19 Antibody Research americanpharmaceuticalreview
December 24, 2020
Fusion Antibodies and Queen’s University Belfast have been awarded a ￡453,000 grant from Invest Northern Ireland to further expand their COVID-19 targeted research and development efforts.
FDA Authorizes COVID-19, Flu Combination Test with Home-Collected Samples americanpharmaceuticalreview
December 24, 2020
?The U.S. Food and Drug Administration (FDA) authorized the first diagnostic test for at home collection of patient samples to detect both COVID-19 and influenza A and B (flu).
INOVIO Doses First Subject in INO-4800 Trial to Prevent COVID-19 americanpharmaceuticalreview
December 24, 2020
INOVIO has dosed its first subject in a Phase 2 clinical trial evaluating DNA medicine INO-4800, its COVID-19 vaccine candidate, as part of its Phase 2/3 clinical trial, called INNOVATE (INovio INO-4800 Vaccine Trial for Efficacy).
Dr. Reddy’s seeks approval from Health Canada for Covid-19 treatment pharmaceutical-technology
December 24, 2020
Dr. Reddy’s Canada has filed an application with Health Canada on behalf of the consortium for Reeqonus (favipiravir) tablets for acute treatment of mild to moderate Covid-19 in adult patients.
Scientists say UK strain unlikely to affect efficacy of COVID-19 vaccines, warn against more mutations expresspharma
December 24, 2020
The faster spreading coronavirus strain first detected in the UK is unlikely to make vaccines less effective as of now but the preventives may need to be appropriately altered if more mutations occur over time, say scientists.
US vaccine rollout’s next challenge: Verifying who is ‘essential’ expresspharma
December 24, 2020
The vaccination campaign under way is now focused on hospital staff and nursing homes, tightly controlled environments.
Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19 prnasia
December 23, 2020
Hyundai Bioscience announced on the 23rd, December 2020, that CNPharm, its major shareholding bio tech company, has succeeded in developing 'Poly-COV01,' an injection drug for the potential treatment of patients with severe cases of COVID-19.
Lilly to begin pragmatic study of bamlanivimab for COVID-19 in New Mexico pharmaceutical-business-review
December 23, 2020
Eli Lilly and Company announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with COVID-19, in collaboration with major local institutions in the state of New Mexico.
UK identifies new SARS-CoV-2 strain that spreads faster pharmaceutical-technology
December 22, 2020
The UK has identified a new variant of Covid-19 through Public Health England’s genomic surveillance and confirmed that it could spread faster.
Pfizer and BioNTech get EU authorisation for COVID-19 Vaccine expresspharma
December 22, 2020
Pfizer and BioNTech announced that the European Commission (EC) has granted a conditional marketing authorisation (CMA) to Pfizer and BioNTech for COMIRNATY (also known as BNT162b2), for active immunisation to prevent COVID-19 caused by SARS-CoV-2 ...